Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Partners with Navigenics to Offer Personal Genetics Service

NEW YORK (GenomeWeb News) - Affymetrix and personal genetics startup Navigenics are teaming up to provide consumers with an understanding of their genetic predisposition for developing certain medical conditions.
 
Under that pact, which Affymetrix President Kevin King disclosed this week at the UBS Global Life Sciences Conference in New York, consumers will be able to go to the Navigenics website and order a saliva collection kit. The customer will then send the kit to Affymetrix’s CLIA lab, which will run a whole-genome screen and send the analysis to Navigenics. Then, Navigenics will provide the genetic-predisposition analysis to the customer via a secure, private web portal and offer genetic counseling.
 
Neither Affymetrix nor Navigenics, which has been funded by venture capital firms Kleiner Perkins and Sequoia Capital, has disclosed the cost of the service or its launch date, but Affymetrix officials said the firm is “realistic” and does not expect the alliance to provide it any significant revenue in the near term.
 
King added that the potential of combining electronic health records with the personal genetics service could eventually help healthcare providers and researchers better understand the role that environmental factors play in disease.
 
Navigenics is offering a similar service to that of another consumer genotyping startup, 23andMe. GenomeWeb Daily News sister publication BioArray News reported last month that Illumina had inked a partnership with 23andMe under which it would provide the company customized SNP arrays.
 
News of the alliance between Affymetrix and Navigenics was first reported in yesterday's issue of GenomeWeb Daily News sister publication BioCommerce Week.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more